S100B and Parkinson disease: They also argued that in experimental models of diseases such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, multiple sclerosis, traumatic and vascular acute neural injury, epilepsy, and inflammatory bowel disease, changes of S100B levels are associated with the occurrence of clinical and/or toxic parameters [13].